Camall Company

C-C 102

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;102 and the representation of a tablet;Lined for the color green; wherein the mark is characterized by a round tablet colored green with CC and design imprinted on it.;

C-C 105

pharmaceutical preparations, namely, phendimetrazine tartrate for use in the treatment of obesity;105 and the representation of a tablet;The accompanying drawing lined for the color pink; wherein the mark is characterized by a round tablet colored pink with CC and design imprinted on it on one side and a cross imprinted on the other side.;

C-C 105

pharmaceutical preparations, namely, phendimetrazine tartrate for use in the treatment of obesity;the representation of a tablet and the numerals 105;The accompanying drawing lined for the color gray; wherein the mark is characterized by a round tablet colored gray with CC and design imprinted on it on one side.;

C-C 105

The mark is characterized by a round, white tablet with CC and design imprinted on one side and a cross imprinted on the other side.;pharmaceutical preparations, namely, phendimetrazine tartrate for use in the treatment of obesity;105 and the representation of a tablet;

C-C 232

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;the representation of the tablet;The drawing is lined for the color yellow.;

C-C 232

PHARMACEUTICAL PREPARATIONS, NAMELY PHENTERMINE HYDROCHLORIDE FOR USE IN THE TREATMENT OF OBESITY;the representation of the tablet;The drawing is lined for the color blue; the mark is characterized by having blue specks randomly located on a white background with C-C 232 and design imprinted on it.;

CC

Pharmaceutical Preparations;

CC

pharmaceutical preparations, namely, phendimetrazine tartrate for use in the treatment of obesity;CAMALL COMPANY;the representation of a tablet;The drawing is lined for the color blue.;

CC 0147

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;the representation of a capsule and 0147;The drawing is lined for the color yellow; wherein the mark is characterized by a gelatin capsule colored in neon yellow with CC and design imprinted on it.;

CC 0147

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;CAMALL COMPANY;0147 and the representation of a capsule;The drawing is lined for the color blue. The accompanying drawing is lined for the color blue.;

CC 0147

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;0147 and the representation of a capsule;The drawing is lined for the color black; wherein the mark is characterized by a gelatin capsule colored in black with CC.;

CC 107

The mark is characterized by a round tablet colored yellow with CC and design imprinted on it.;pharmaceutical preparations, namely, phendimetrazine tartrate for use in the treatment of obesity;107 and the representation of a tablet;The drawing is lined for the color yellow.;

CC 109

The mark as shown in the accompanying drawing characterized by a round white tablet with CC and design imprinted on it.;pharmaceutical preparations, namely, diethylpropion hydrochloride for use in the treatment of obesity;109 and the representation of a tablet;

CC 18.75

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;18.75 and the representation of a capsule;The drawing is lined for the colors yellow and gray; wherein the mark is characterized by a gelatin capsule colored one half gray and one half yellow with CC and design imprinted.;

CC 37.5

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;CC 375;37.5 and the representation of a capsule;The mark is lined for the color yellow.;

CC 37.5

The mark is characterized by a gelatin capsule colored one half brown and the other half clear containing orange and white beads inside with CC and design imprinted on it.;pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;37.5 and the representation of a capsule;The mark as shown in the accompanying drawing lined for the color brown and orange.;

CC 37.5

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;37.5 and the representation of a capsule;Lined for the colors black and red; wherein the mark is characterized by a gelatin capsule colored one half black and one half red with the CC and design imprinted on it.;

CC 37.5

pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;37.5 and the representation of a capsule;The mark is lined for the color yellow.;

CC 37.5

The mark is characterized by a gelatin capsule colored in neon yellow with CC and design imprinted on it.;pharmaceutical preparations, namely, phentermine hydrochloride for use in the treatment of obesity;CAMALL COMPANY 37.5;37.5 and the representation of a capsule;The drawing is lined for the color yellow.;

CC 37.5

PHARMACEUTICAL PREPARATIONS, NAMELY, PHENTERMINE HYDROCHLORIDE FOR USE IN THE TREATMENT OF OBESITY;37.5;

E.M.S.

distributorships featuring pharmaceutical drugs;

PICHROME

nutritional supplements; namely, biologically active chromium;

ZINCHROME

pharmaceutical products, namely, dietary mineral supplements;ZINC-CHROME;